Covagen and Roche start collaboration
Covagen and Roche announced that they have entered a collaboration agreement under which Covagen will use its protein engineering technology to isolate Fynomers – a novel class of protein-based drugs - binding to undisclosed targets provided by Roche. Fynomers delivered by Covagen will be further tested and evaluated by Roche to discover potential new treatments for patients with unmet medical needs. The financial terms of the collaboration agreement were not disclosed.
Dr. Julian Bertschinger, CEO and co-founder of Covagen commented: “We are proud to enter a collaboration with Roche, one of the leading science-based healthcare companies in the field of biopharmaceuticals.”
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.